RENOVACARE INC (RCAR) Financials

RCAR

FY2021 annual

Revenue Not reported for FY2021

Net Income -$4.5M +53.2% YoY

EPS (Diluted) Not reported for FY2021

Operating Cash Flow -$4.6M +3.4% YoY

Source SEC Filings (10-K/10-Q) Latest period Q3 FY2022, ended Sep 30, 2022 Reported Nov 18, 2022 Currency USD FYE December

Newest figures come from the 10-Q for Q3 FY2022, filed Nov 18, 2022. Each column of the statement tables below links to the filing it was taken from.

This page shows RENOVACARE INC (RCAR) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 12 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Financial health score not available

RENOVACARE INC does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Piotroski F-Score Partial

1/6

RENOVACARE INC passes 1 of 6 computable financial strength tests (3 of the nine could not be computed from available data). No profitability signals pass, 1 of 2 leverage/liquidity signals pass.

Earnings Quality No Cash Backing

N/A

RENOVACARE INC reported a net loss of $4.5M while operations used $4.6M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Interest Coverage At Risk

N/A

RENOVACARE INC reported an operating loss of $5.4M against $6K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

EBITDA

-$1.9M

YoY-10.5%

QoQ+11.7%

RENOVACARE INC's EBITDA was -$1.9M in Q3 2022, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 10.5% from the same quarter a year earlier. Against the prior quarter it is up 11.7%.

Net Income

-$400K

YoY+76.4%

QoQ+82.4%

RENOVACARE INC reported -$400K in net income in Q3 2022. This represents an increase of 76.4% from the same quarter a year earlier. Against the prior quarter it is up 82.4%.

Revenue

Not reported for Q3 2022.

EPS (Diluted)

Not reported for Q3 2022.

Cash & Balance Sheet

Cash & Debt

$101K

YoY-97.1%

QoQ-58.7%

5Y CAGR-38.5%

10Y CAGR-16.0%

RENOVACARE INC held $101K in cash as of Q3 2022; long-term debt is not reported for that period.

Shares Outstanding

87M

YoY0.0%

QoQ0.0%

5Y CAGR+2.8%

10Y CAGR+3.3%

RENOVACARE INC had 87M shares outstanding in Q3 2022. That is unchanged from the same quarter a year earlier. It is unchanged from the prior quarter.

Free Cash Flow

Not reported for Q3 2022.

Dividends Per Share

Not reported for Q3 2022.

Margins & Returns

None of these metrics is reported for Q3 2022.

Capital Allocation

R&D Spending

$388K

YoY-47.9%

QoQ+2.3%

RENOVACARE INC invested $388K in research and development in Q3 2022. This represents a decrease of 47.9% from the same quarter a year earlier. Against the prior quarter it is up 2.3%.

Share Buybacks

Not reported for Q3 2022.

Capital Expenditures

Not reported for Q3 2022.

RCAR Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

RCAR quarterly income statement

Metric	TTM	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K	FY1010-K
Revenue	N/A	N/A	$0	$0	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	$3.2M-22.5%	$4.1M+454.2%	$746K+102.2%	$369K-35.7%	$574K+85.5%	$310K+10.1%	$281K-71.2%	$976K	N/A	N/A	$37K	N/A
SG&A Expenses	N/A	$2.2M-60.2%	$5.5M+88.3%	$2.9M+79.6%	$1.6M-22.7%	$2.1M+33.5%	$1.6M+53.2%	$1.0M-10.2%	$1.2M+83.9%	$629K+173.8%	$230K-57.2%	$536K+66.2%	$323K
Operating Income	N/A	-$5.4M+44.1%	-$9.7M-162.2%	-$3.7M-83.8%	-$2.0M+25.5%	-$2.7M-42.0%	-$1.9M-44.0%	-$1.3M	N/A	N/A	-$244K+69.2%	-$793K-104.8%	-$387K
EBITDA	N/A	-$5.4M+44.2%	-$9.7M-162.2%	-$3.7M-83.8%	-$2.0M+25.5%	-$2.7M-42.0%	-$1.9M	N/A	N/A	N/A	N/A	N/A	N/A
Interest Expense	N/A	$6K-95.0%	$129K-61.2%	$332K+332.4%	$77K-0.6%	$77K+407.8%	$15K	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	N/A	-$4.5M+53.2%	-$9.5M-184.3%	-$3.4M-58.3%	-$2.1M+42.5%	-$3.7M-77.6%	-$2.1M-57.6%	-$1.3M+38.1%	-$2.1M-106.4%	-$1.0M-323.3%	-$244K-105.5%	$4.5M+204.5%	-$4.3M
EPS (Basic)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$0.07+200.0%	-$0.07
EPS (Diluted)	—	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-$0.03-200.0%	-$0.01	$0.00-100.0%	$0.07+200.0%	-$0.07
Diluted Shares (Avg)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	63M0.0%	63M

Metric	Q3'2210-Q	Q2'2210-Q	Q1'2210-Q	Q4'2110-Q	Q3'2110-Q	Q2'2110-Q	Q1'2110-Q	Q4'2010-K
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	$0	N/A
R&D Expenses	$388K-47.9%	$379K-46.2%	$596K-43.4%	N/A	$745K-52.0%	$705K-47.7%	$1.1M+446.9%	N/A
Operating Income	-$1.9M-10.4%	-$2.1M-92.6%	N/A	N/A	-$1.7M+40.2%	-$1.1M+63.7%	-$517K+57.9%	N/A
EBITDA	-$1.9M-10.5%	-$2.1M-92.8%	N/A	N/A	-$1.7M	-$1.1M	-$515K+58.1%	N/A
Interest Expense	$2K-8.3%	$2K-22.6%	$289+4028.6%	N/A	$2K-91.0%	$3K-92.0%	$7-100.0%	N/A
Net Income	-$400K+76.4%	-$2.3M-149.1%	-$1.7M-234.0%	N/A	-$1.7M+39.7%	-$912K+69.7%	-$517K+56.0%	N/A

Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, SG&A Expenses, Income Tax, EPS (Basic), EPS (Diluted), Diluted Shares (Avg).

RCAR Balance Sheet

RCAR quarterly balance sheet

Metric	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K	FY1010-K
Total Assets	$3.7M-56.5%	$8.4M-32.5%	$12.4M-20.9%	$15.7M+413.6%	$3.1M+407.3%	$603K+7.6%	$561K-34.3%	$853K-51.3%	$1.8M+64.5%	$1.1M-20.5%	$1.3M-35.6%	$2.1M
Current Assets	$3.4M-57.6%	$8.0M-35.1%	$12.3M-21.1%	$15.6M+435.5%	$2.9M+546.6%	$450K+10.2%	$408K-40.9%	$691K-54.3%	$1.5M+189.3%	$522K-34.9%	$802K-61.0%	$2.1M
Cash & Equivalents	$2.8M-61.6%	$7.4M-39.2%	$12.2M-20.9%	$15.4M+429.8%	$2.9M+595.2%	$418K+5.1%	$398K-41.8%	$683K-54.7%	$1.5M+193.8%	$514K-34.8%	$788K-61.6%	$2.1M
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$800-94.5%	$15K+455.0%	$3K
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$1.3M-0.9%	$1.3M+369.2%	$281K-28.5%	$393K-71.9%	$1.4M+283.5%	$364K+8.4%	$336K-11.4%	$379K+583.7%	$55K-43.5%	$98K-24.0%	$129K-97.6%	$5.3M
Current Liabilities	$1.3M+1.3%	$1.3M+359.0%	$281K-28.5%	$393K+9.3%	$359K-1.3%	$364K+54.4%	$236K+17.3%	$201K+262.4%	$55K+36.7%	$41K-45.0%	$74K-98.6%	$5.3M
Non-Current Liabilities	$0-100.0%	$29K	$0	$0-100.0%	$1.0M	$0-100.0%	$100K-43.9%	$178K	$0-100.0%	$58K+4.0%	$55K+5.2%	$53K
Total Equity	$2.3M-66.8%	$7.1M-41.8%	$12.2M-20.7%	$15.3M+820.8%	$1.7M+595.5%	$239K+6.4%	$225K-52.6%	$474K-72.1%	$1.7M+75.4%	$968K-20.1%	$1.2M+137.4%	-$3.2M
Retained Earnings	-$34.2M-15.0%	-$29.8M-47.2%	-$20.2M-19.9%	-$16.9M-14.4%	-$14.7M-33.4%	-$11.1M-23.2%	-$9.0M-17.2%	-$7.7M-38.6%	-$5.5M-23.0%	-$4.5M-5.7%	-$4.2M+51.2%	-$8.7M

Metric	Q3'2210-Q	Q2'2210-Q	Q1'2210-Q	Q4'2110-Q	Q3'2110-Q	Q2'2110-Q	Q1'2110-Q	Q4'2010-K
Total Assets	$1.1M-74.8%	$1.4M-72.1%	$3.0M-53.3%	$3.7M-56.5%	$4.2M-55.4%	$5.2M-52.4%	$6.4M-45.6%	$8.4M-32.5%
Current Assets	$1.1M-72.8%	$1.4M-71.0%	$2.8M-54.3%	$3.4M-57.6%	$3.9M-56.6%	$4.8M-54.9%	$6.1M-48.1%	$8.0M-35.1%
Cash & Equivalents	$101K-97.1%	$244K-94.4%	$1.9M-66.7%	$2.8M-61.6%	$3.4M-60.5%	$4.3M-57.7%	$5.6M-50.7%	$7.4M-39.2%
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$2.5M+252.6%	$2.7M+1117.0%	$2.2M+179.1%	$1.3M-0.9%	$713K-11.3%	$221K-72.3%	$784K+90.6%	$1.3M+369.2%
Current Liabilities	$1.7M+139.8%	$1.9M+771.5%	$1.4M+81.1%	$1.3M+1.3%	$713K-6.4%	$217K-72.8%	$766K+86.3%	$1.3M+359.0%
Non-Current Liabilities	$804K	$802K+17998.7%	$800K+4452.5%	$0-100.0%	$0-100.0%	$4K	$18K	$29K
Total Equity	-$1.5M-142.0%	-$1.3M-125.5%	$821K-85.5%	$2.3M-66.8%	$3.5M-59.5%	$4.9M-50.8%	$5.7M-50.5%	$7.1M-41.8%
Retained Earnings	-$38.6M-17.5%	-$38.2M-22.6%	-$36.0M-18.8%	-$34.2M-15.0%	-$32.9M-20.8%	-$31.2M-27.8%	-$30.3M-41.6%	-$29.8M-47.2%

Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.

RCAR Cash Flow Statement

RCAR quarterly cash flow statement

Metric	TTM	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K	FY1010-K
Operating Cash Flow	-$4.1M	-$4.6M+3.4%	-$4.7M-47.0%	-$3.2M-58.5%	-$2.0M-21.0%	-$1.7M+6.4%	-$1.8M-38.1%	-$1.3M-56.9%	-$826K-136.0%	-$350K-30.9%	-$267K+64.3%	-$747K-114.7%	-$348K
Depreciation & Amortization	N/A	$9K+255.8%	$3K+897.3%	$264-16.7%	$3170.0%	$317+498.1%	$53	N/A	N/A	N/A	N/A	N/A	N/A
Stock-Based Compensation	N/A	-$173K-104.1%	$4.2M+2099.3%	$191K+12.2%	$171K-81.1%	$904K+205.3%	$296K+400.9%	$59K-1.2%	$60K+287.7%	$15K	N/A	N/A	-$36K
Capital Expenditures	N/A	N/A	$41K	$0	N/A	N/A	$951	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	-$4.8M-48.3%	-$3.2M	N/A	N/A	-$1.8M	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	-$49K	$0	N/A	N/A	-$951	N/A	N/A	-$160K-2196.1%	-$7K+98.6%	-$513K-5414.0%	-$9K
Financing Cash Flow	N/A	N/A	N/A	N/A	$14.5M+248.8%	$4.2M+130.0%	$1.8M+79.2%	$1.0M	N/A	$1.5M	N/A	N/A	N/A

Metric	Q3'2210-Q	Q2'2210-Q	Q1'2210-Q	Q4'2110-Q	Q3'2110-Q	Q2'2110-Q	Q1'2110-Q	Q4'2010-K
Operating Cash Flow	-$148K+83.9%	-$1.6M-28.5%	-$1.8M+1.4%	-$573K+54.5%	-$921K+40.4%	-$1.3M-12.5%	-$1.8M-127.0%	-$1.3M-5.8%
Depreciation & Amortization	$0-100.0%	$2K-3.2%	$2K-0.1%	$2K-0.1%	$2K	$2K	$2K	$2K+8507.4%
Stock-Based Compensation	N/A	N/A	$223K+125.5%	N/A	$246K-78.0%	$244K-84.6%	-$875K-287.8%	N/A
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$0
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-$1.3M-5.8%
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	$0+100.0%	$0
Financing Cash Flow	$0	$0	$800K	N/A	N/A	N/A	N/A	N/A

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

RCAR Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

RCAR quarterly financial ratios

Metric	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K	FY1010-K
Return on Equity	-190.5%-55.6pp	-134.9%-107.3pp	-27.6%-13.8pp	-13.8%+207.8pp	-221.6%+646.6pp	-868.2%-282.1pp	-586.1%-136.8pp	-449.3%-388.5pp	-60.8%-35.6pp	-25.2%-393.1pp	367.9%	N/A
Return on Assets	-122.4%-8.7pp	-113.7%-86.7pp	-27.0%-13.5pp	-13.5%+107.1pp	-120.5%+223.9pp	-344.4%-109.3pp	-235.1%+14.6pp	-249.8%-190.8pp	-58.9%-36.0pp	-22.9%-355.4pp	332.5%+537.4pp	-205.0%
Current Ratio	2.59-3.6x	6.19-37.6x	43.77+4.1x	39.64+31.6x	8.09+6.9x	1.24-0.5x	1.73-1.7x	3.44-23.8x	27.24+14.4x	12.87+2.0x	10.89+10.5x	0.39
Debt-to-Equity	0.56+0.4x	0.19+0.2x	0.020.0x	0.03-0.8x	0.84-0.7x	1.520.0x	1.49+0.7x	0.80+0.8x	0.03-0.1x	0.100.0x	0.11	N/A
Asset Turnover	N/A	0.000.0x	0.00	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'2210-Q	Q2'2210-Q	Q1'2210-Q	Q4'2110-Q	Q3'2110-Q	Q2'2110-Q	Q1'2110-Q	Q4'2010-K
Return on Equity	N/A	N/A	-210.4%-201.3pp	N/A	-48.8%-16.0pp	-18.5%+11.5pp	-9.1%+1.1pp	N/A
Return on Assets	-37.9%+2.6pp	-158.3%-140.6pp	-57.4%-49.4pp	N/A	-40.5%-10.5pp	-17.7%+10.1pp	-8.0%+1.9pp	N/A
Current Ratio	0.62-4.8x	0.74-21.5x	2.00-5.9x	2.59-3.6x	5.45-6.3x	22.20+8.8x	7.92-20.5x	6.19-37.6x
Debt-to-Equity	N/A	N/A	2.67+2.5x	0.56+0.4x	0.20+0.1x	0.040.0x	0.14+0.1x	0.19+0.2x
Asset Turnover	N/A	N/A	N/A	N/A	N/A	N/A	0.000.0x	N/A

Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
RENOVACARE INC RCAR	FY2021	N/A	-$4.5M	N/A	$9K	—
VIRPAX PHARMS INC VRPX	FY2024	N/A	N/A	N/A	N/A	—
NOVACCESS GLOBAL INC XSNX	FY2024	$0	N/A	N/A	$6K	—
BETTER THERAPEUTICS INC BTTX	FY2022	N/A	-$39.8M	N/A	$5K	—

Where RENOVACARE INC Ranks

Frequently Asked Questions

Is RENOVACARE INC profitable?

No, RENOVACARE INC (RCAR) reported a net income of -$4.5M in fiscal year 2021.

What is RENOVACARE INC's EBITDA?

RENOVACARE INC (RCAR) had EBITDA of -$5.4M in fiscal year 2021, measuring earnings before interest, taxes, depreciation, and amortization.

What is RENOVACARE INC's return on equity (ROE)?

RENOVACARE INC (RCAR) has a return on equity of -190.5% for fiscal year 2021, measuring how efficiently the company generates profit from shareholder equity.

What is RENOVACARE INC's operating cash flow?

RENOVACARE INC (RCAR) recorded an outflow of $4.6M in operating cash flow during fiscal year 2021, representing cash used by core business activities.

What are RENOVACARE INC's total assets?

RENOVACARE INC (RCAR) had $3.7M in total assets as of fiscal year 2021, including both current and long-term assets.

How much does RENOVACARE INC spend on research and development?

RENOVACARE INC (RCAR) invested $3.2M in research and development during fiscal year 2021.

How many shares does RENOVACARE INC have outstanding?

RENOVACARE INC (RCAR) had 87M shares outstanding as of fiscal year 2021.

What is RENOVACARE INC's current ratio?

RENOVACARE INC (RCAR) had a current ratio of 2.59 as of fiscal year 2021, which is generally considered healthy.

What is RENOVACARE INC's debt-to-equity ratio?

RENOVACARE INC (RCAR) had a debt-to-equity ratio of 0.56 as of fiscal year 2021, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is RENOVACARE INC's return on assets (ROA)?

RENOVACARE INC (RCAR) had a return on assets of -122.4% for fiscal year 2021, measuring how efficiently the company uses its assets to generate profit.

How does RENOVACARE INC's liquidity compare with its operating cash outflow?

At the end of fiscal year 2021, RENOVACARE INC (RCAR) held $2.8M in cash, cash equivalents and investments, and reported an operating cash outflow of $4.6M over that year. Dividing the one by the other, the reported balance equals about 7 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

What is RENOVACARE INC's Piotroski F-Score?

RENOVACARE INC (RCAR) has a Piotroski F-Score of 1 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are RENOVACARE INC's earnings high quality?

RENOVACARE INC (RCAR) reported a net loss of $4.5M while operations used $4.6M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can RENOVACARE INC cover its interest payments?

RENOVACARE INC (RCAR) reported an operating loss of $5.4M against $6K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.